Cystic Acne Companies

Almirall's Seysara (sarecycline) Launched in the US in June 2021, this novel tetracycline-derived oral antibiotic specifically targets inflammatory and nodular acne, including cystic lesions.

Galderma's Epiduo Forte combination topical treatment of adapalene and benzoyl peroxide received an expanded FDA indication in February 2023 for moderate-to-severe acne, including inflammatory and cystic lesions.

Several promising therapies in clinical trials Dermavant Sciences and Inviragen are investigating novel oral and topical drugs targeting specific inflammatory pathways or bacterial strains involved in cystic acne development.

List of Cystic Acne Key Companies in the Market

• GlaxoSmithKline plc (U.K)


• Pfizer Inc. (U.S.)


• Abbott Laboratories (U.S.)


• Hexal AG (Germany)


• Hoffmann-La Roche Ltd (Switzerland)


• Alma Lasers Inc. (Israel)


• Bristol-Myers Squibb Company (U.S.)


• GE Healthcare (U.K)


• National Biological Corp. (U.S.)


• Herbert Waldmann GmbH & Co. KG (Germany)


• Sylvan Company (U.S.)


• DUSA Pharmaceuticals Inc. (U.S.)